Hutch News

Hutch News

Stories tagged 'Seattle Cancer Care Alliance (SCCA)'

Palliative care: It’s not what you think (or fear)

Stigma keeps many cancer patients from using a service that offers much-needed help to the sick as well as the dying

April 26, 2017 | By Diane Mapes / Fred Hutch News Service

Palliative care isn't just about easing suffering at end of life. It’s also appropriate for patients dealing with pain or side effects anywhere along the cancer continuum. But not all patients, or doctors, realize this. Two Fred Hutch experts discuss the latest research, and the stigma, surrounding this crucial type of care.

View story >

‘A place where miracles happen’: Opening of Bezos Family Immunotherapy Clinic highlights patient-focused science

Research symposium and ribbon cutting celebrates first-of-its-kind facility for experimental immunotherapies

Dec. 16, 2016 | By Susan Keown / Fred Hutch News Service

Lymphoma survivor Stephanie Florence said she wouldn't be alive if not for the science done at Fred Hutchinson Cancer Research Center. This week, she cut the ribbon at the grand opening of the Bezos Family Immunotherapy Clinic, which will make it possible for twice as many patients like Florence to receive treatment.

View story >

The ‘cancer Olympics’: Why envy, rivalry exist among some patients

Survivors often compare their cancers — a normal yet potentially unhealthy exercise, experts say

Dec. 15, 2016 | By Bill Briggs / Fred Hutch News Service

It's natural for cancer patients to compare their diseases and outcomes, but some comparisons become competitive, creating envy, hard feelings and divisions.

View story >

Three's a charm in a triple-drug combination for transplant patients

A drug with a storied past offers a new edge against an old foe

Dec. 4, 2016 | By Sabin Russell / Fred Hutch News Service

Discovered nearly 45 years ago in the volcanic soils of fabled Easter Island in the Pacific, a drug first thought of as an antifungal agent has found a new purpose by boosting the survival of leukemia patients after blood stem cell transplants. In a clinical trial conducted by Fred Hutchinson Cancer Research Center, the addition of a third drug, sirolimus, to a standard two-drug regimen effectively cut in half the incidence of acute graft-vs.-host disease, or GVHD, a common and dangerous complication of these lifesaving procedures.

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.